Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03362931




Registration number
NCT03362931
Ethics application status
Date submitted
30/11/2017
Date registered
5/12/2017
Date last updated
17/05/2023

Titles & IDs
Public title
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
Scientific title
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
Secondary ID [1] 0 0
1924-701-007
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glaucoma 0 0
Angle-Closure 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - XEN45

Experimental: XEN45 Glaucoma Treatment System (hereafter referred to as XEN) - XEN45 unilaterally implanted in the study eye


Treatment: Devices: XEN45
XEN45 unilaterally implanted in the study eye
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving at Least a 20% Reduction From Baseline Hour 0 IOP While on the Same Number or Fewer IOP Lowering Medications at Month 12
Timepoint [1] 0 0
Month 12
Secondary outcome [1] 0 0
Change From Baseline the Number of Concomitant IOP-lowering Medications
Timepoint [1] 0 0
Month 12

Eligibility
Key inclusion criteria
- Diagnosis of ACG defined as areas of iridotrabecular contact present in = 2 quadrants and glaucomatous damage to optic disc and visual field, in the study eye - Study eye has healthy, free, and mobile conjunctiva in the target quadrant
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Uncontrolled systemic disease (eg, diabetes, hypertension) - Known history of bleeding disorder or prolonged bleeding after surgery or those on pharmacologic blood thinners other than aspirin (up to 100 mg/day) - History of dermatologic keloid formation - Open angle glaucoma, active acute angle closure attack, congenital glaucoma, juvenile glaucoma, secondary glaucoma in the study eye - History of following surgeries in the study eye: o incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions o corneal graft including partial grafts such as Descemet's stripping endothelial keratoplasty and Descemet's membrane endothelial keratoplasty o previous laser or incisional intraocular surgery that might interfere with the outcome of this trial - Previous glaucoma shunt implantation in the target quadrant in the study eye - Active or history of chronic uveitis in the study eye - Unable to discontinue contact lens wear in the study eye during the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/07/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/03/2022
Sample size
Target
Accrual to date
Final
65
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Marsden Eye Specialists Parramatta /ID# 232761 - Paramatta
Recruitment hospital [2] 0 0
Melbourne Eye Specialists /ID# 232767 - Fitzroy
Recruitment hospital [3] 0 0
Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765 - Vermont South
Recruitment postcode(s) [1] 0 0
2150 - Paramatta
Recruitment postcode(s) [2] 0 0
VIC3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3133 - Vermont South
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Quebec
Country [2] 0 0
Canada
State/province [2] 0 0
Mississauga
Country [3] 0 0
Korea, Republic of
State/province [3] 0 0
Seoul
Country [4] 0 0
Singapore
State/province [4] 0 0
Singapore
Country [5] 0 0
Taiwan
State/province [5] 0 0
Taipei
Country [6] 0 0
Taiwan
State/province [6] 0 0
Hualien
Country [7] 0 0
United Kingdom
State/province [7] 0 0
England
Country [8] 0 0
United Kingdom
State/province [8] 0 0
Lancashire
Country [9] 0 0
United Kingdom
State/province [9] 0 0
West Sussex
Country [10] 0 0
United Kingdom
State/province [10] 0 0
Colchester
Country [11] 0 0
United Kingdom
State/province [11] 0 0
Edinburgh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Allergan
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
Trial website
https://clinicaltrials.gov/study/NCT03362931
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ALLERGAN INC.
Address 0 0
Allergan
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03362931